NATCOPHARM.NS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 17:59):

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs)...

Stats
今日成交量	477 542
平均成交量	1.05M
市值	181.98B
EPS	INR0 ( 2024-02-13 )
下一个收益日期	( INR0 ) 2024-05-27
Last Dividend	INR7.00 ( 2023-08-22 )
Next Dividend	INR0 ( N/A )
P/E	14.34
ATR14	INR1.134 (0.11%)

音量相关性

長: 0.05 (neutral)

短: -0.60 (weak negative)

Signal:(43.564) Neutral

NATCO Pharma Limited 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

NATCO Pharma Limited 相关性 - 货币/商品

-0.62
( weak negative )

-0.73
( moderate negative )

-0.79
( moderate negative )

-0.59
( weak negative )

0.41
( neutral )

-0.16
( neutral )

NATCO Pharma Limited 财务报表

Annual	2022
营收:	INR27.07B
毛利润:	INR20.80B (76.83 %)
EPS:	INR39.18

FY	2022
营收:	INR27.07B
毛利润:	INR20.80B (76.83 %)
EPS:	INR39.18

FY	2022
营收:	INR19.05B
毛利润:	INR12.23B (64.22 %)
EPS:	INR9.32

FY	2021
营收:	INR16.90B
毛利润:	INR10.82B (64.04 %)
EPS:	INR24.20

Financial Reports:

No articles found.

NATCO Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR3.50 (N/A)	INR0.750 (N/A)	INR1.250 (N/A)	INR0 (N/A)	INR7.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

NATCO Pharma Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 1.998 - low (50.00%) | Divividend Growth Potential Score: 3.27 - Decrease likely (34.50%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.200	1996-12-31
Last Dividend	INR7.00	2023-08-22
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	33	--
Total Paid Out	INR56.90	--
Avg. Dividend % Per Year	0.68%	--
Score	2.39	--
Div. Sustainability Score	1.998
Div.Growth Potential Score	3.27
Div. Directional Score	2.64	--

Next Divdend (Est)
(2024-07-24)

INR7.62 Estimate 6.47 %

Dividend Stability

0.26 Very Poor

Dividend Score

2.39

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1996	INR0	0.00%
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR8.50	1.07%
2019	INR7.00	1.01%
2020	INR8.75	1.42%
2021	INR3.50	0.36%
2022	INR6.25	0.68%
2023	INR8.25	1.49%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHRIPISTON.NS	Dividend Junior	2023-06-27	Semi-Annually	9	0.89%
MATRIMONY.NS	Dividend Junior	2023-08-03	Annually	7	0.41%
GRWRHITECH.NS	Dividend Junior	2023-09-20	Semi-Annually	3	0.88%
BANDHANBNK.NS	Dividend Junior	2023-08-11	Sporadic	7	0.20%
PPAP.NS	Ex Dividend Junior	2023-09-08	Annually	17	0.34%
JWL.NS	Dividend Junior	2023-09-12	Insufficient data to determine frequency	2	0.17%
DSSL.NS	Dividend Junior	2023-08-23	Annually	6	0.34%
ACE.NS	Dividend Junior	2023-08-17	Annually	18	0.23%
SSWL.NS	Dividend Junior	2023-08-14	Annually	20	0.30%
MSUMI.NS	Dividend Junior	2023-08-09	Annually	3	0.60%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.334	1.500	3.32	4.99	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.251	1.500	8.32	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	97.83	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	19.24	2.00	3.59	7.17	[0 - 30]
freeCashFlowPerShareTTM	19.24	2.00	0.380	0.760	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.783	1.000	0.290	0.290	[0.2 - 0.8]
operatingProfitMarginTTM	0.401	1.000	3.98	3.98	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.998

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	14.34	1.000	8.65	0	[1 - 100]
returnOnEquityTTM	0.251	2.50	8.92	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	19.24	2.00	3.59	0.760	[0 - 30]
dividendYielPercentageTTM	0.928	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	19.24	2.00	3.59	7.17	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-3.21	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0900	1.000	-0.250	0	[0.1 - 0.5]
Total Score				3.27

NATCO Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.